Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 1
2016 1
2017 2
2019 1
2020 1
2023 3
2024 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Diagnostic accuracy of a three-gene Mycobacterium tuberculosis host response cartridge using fingerstick blood for childhood tuberculosis: a multicentre prospective study in low-income and middle-income countries.
Olbrich L, Verghese VP, Franckling-Smith Z, Sabi I, Ntinginya NE, Mfinanga A, Banze D, Viegas S, Khosa C, Semphere R, Nliwasa M, McHugh TD, Larsson L, Razid A, Song R, Corbett EL, Nabeta P, Trollip A, Graham SM, Hoelscher M, Geldmacher C, Zar HJ, Michael JS, Heinrich N; RaPaed-TB consortium. Olbrich L, et al. Lancet Infect Dis. 2024 Feb;24(2):140-149. doi: 10.1016/S1473-3099(23)00491-7. Epub 2023 Oct 30. Lancet Infect Dis. 2024. PMID: 37918414 Free PMC article.
Effect of seven anti-tuberculosis treatment regimens on sputum microbiome: a retrospective analysis of the HIGHRIF study 2 and PanACEA MAMS-TB clinical trials.
Musisi E, Wyness A, Eldirdiri S, Dombay E, Mtafya B, Ntinginya NE, Heinrich N, Kibiki GS, Hoelscher M, Boeree M, Aarnoutse R, Gillespie SH, Sabiiti W; PanACEA consortium. Musisi E, et al. Lancet Microbe. 2023 Nov;4(11):e913-e922. doi: 10.1016/S2666-5247(23)00191-X. Epub 2023 Oct 10. Lancet Microbe. 2023. PMID: 37832571 Free article.
Expanding Xpert MTB/RIF Ultra® and LF-LAM testing for diagnosis of tuberculosis among HIV-positive adults admitted to hospitals in Tanzania and Mozambique: a randomized controlled trial (the EXULTANT trial).
Mangu C, Cossa M, Ndege R, Khosa C, Leukes V, de la Torre-Pérez L, Machiana A, Kivuma B, Mnzava D, Zachariah C, Manjate P, Tagliani E, Schacht C, Buech J, Singh S, Ehrlich J, Riess F, Sanz S, Kranzer K, Cox H, Sabi I, Nguenha D, Meggi B, Weisser M, Ntinginya N, Schumacher S, Ruhwald M, Penn-Nicholson A, Garcia-Basteiro AL; TB-CAPT Consortium. Mangu C, et al. BMC Infect Dis. 2024 Aug 15;24(1):831. doi: 10.1186/s12879-024-09651-z. BMC Infect Dis. 2024. PMID: 39148008 Free PMC article. Clinical Trial.
Protein binding of rifampicin is not saturated when using high-dose rifampicin.
Litjens CHC, Aarnoutse RE, van Ewijk-Beneken Kolmer EWJ, Svensson EM, Colbers A, Burger DM, Boeree MJ, Te Brake LHM; PanACEA-MAMS-TB-01 Team. Litjens CHC, et al. J Antimicrob Chemother. 2019 Apr 1;74(4):986-990. doi: 10.1093/jac/dky527. J Antimicrob Chemother. 2019. PMID: 30597025 Clinical Trial.
Sequential and parallel testing for microbiological confirmation of tuberculosis disease in children in five low-income and middle-income countries: a secondary analysis of the RaPaed-TB study.
Olbrich L, Franckling-Smith Z, Larsson L, Sabi I, Ntinginya NE, Khosa C, Banze D, Nliwasa M, Corbett EL, Semphere R, Verghese VP, Michael JS, Ninan MM, Saathoff E, McHugh TD, Razid A, Graham SM, Song R, Nabeta P, Trollip A, Nicol MP, Hoelscher M, Geldmacher C, Heinrich N, Zar HJ; RaPaed-AIDA-TB consortium. Olbrich L, et al. Lancet Infect Dis. 2024 Sep 20:S1473-3099(24)00494-8. doi: 10.1016/S1473-3099(24)00494-8. Online ahead of print. Lancet Infect Dis. 2024. PMID: 39312914 Free article.
Reflex Xpert MTB/XDR Testing of Residual Rifampicin-Resistant Specimens: A Clinical Laboratory-Based Diagnostic Accuracy and Feasibility Study in South Africa.
Centner CM, Munir R, Tagliani E, Rieß F, Brown P, Hayes C, Dolby T, Zemanay W, Cirillo DM, David A, Schumacher SG, Denkinger CM, Ruhwald M, Leukes VN, Nicol MP, Van der Walt I, Kisten G, Gumede M, Mace A, Brink A, Stevens W, Scott L, Penn-Nicholson A, Cox H; TB-CAPT Consortium. Centner CM, et al. Open Forum Infect Dis. 2024 Jul 31;11(8):ofae437. doi: 10.1093/ofid/ofae437. eCollection 2024 Aug. Open Forum Infect Dis. 2024. PMID: 39165581 Free PMC article.
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.
Boeree MJ, Heinrich N, Aarnoutse R, Diacon AH, Dawson R, Rehal S, Kibiki GS, Churchyard G, Sanne I, Ntinginya NE, Minja LT, Hunt RD, Charalambous S, Hanekom M, Semvua HH, Mpagama SG, Manyama C, Mtafya B, Reither K, Wallis RS, Venter A, Narunsky K, Mekota A, Henne S, Colbers A, van Balen GP, Gillespie SH, Phillips PPJ, Hoelscher M; PanACEA consortium. Boeree MJ, et al. Among authors: manyama c. Lancet Infect Dis. 2017 Jan;17(1):39-49. doi: 10.1016/S1473-3099(16)30274-2. Epub 2016 Oct 26. Lancet Infect Dis. 2017. PMID: 28100438 Free PMC article. Clinical Trial.
Pharmacokinetics, Tolerability, and Bacteriological Response of Rifampin Administered at 600, 900, and 1,200 Milligrams Daily in Patients with Pulmonary Tuberculosis.
Aarnoutse RE, Kibiki GS, Reither K, Semvua HH, Haraka F, Mtabho CM, Mpagama SG, van den Boogaard J, Sumari-de Boer IM, Magis-Escurra C, Wattenberg M, Logger JGM, Te Brake LHM, Hoelscher M, Gillespie SH, Colbers A, Phillips PPJ, Plemper van Balen G, Boeree MJ; PanACEA Consortium. Aarnoutse RE, et al. Antimicrob Agents Chemother. 2017 Oct 24;61(11):e01054-17. doi: 10.1128/AAC.01054-17. Print 2017 Nov. Antimicrob Agents Chemother. 2017. PMID: 28827417 Free PMC article. Clinical Trial.
11 results